A Phase I/III, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

被引：2
|
作者：
Jurczak, Wojciech [1 ]
Rule, Simon [2 ]
Townsend, William [3 ]
Tucker, David [4 ]
Sarholz, Barbara [5 ]
Scheele, Jurgen [6 ]
Gribben, John G. [7 ]
Zinzani, Pier Luigi [8 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, Krakow, Poland
[2] Plymouth Univ, Dept Haematol, Sch Med, Plymouth, Devon, England
[3] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England
[4] Torbay Hosp, Dept Haematol, Torquay, England
[5] Merck KGaA, R&D Global Biostat & Epidemiol, Darmstadt, Germany
[6] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[7] Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England
[8] Ist Ematol, Bologna, Italy
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-112808
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4161
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
    Aalipour, Amin
    Advani, Ranjana H.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (04) : 121 - 133
  • [32] Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies (Review)
    Xia, Bing
    Qu, Fulian
    Yuan, Tian
    Zhang, Yizhuo
    ONCOLOGY LETTERS, 2015, 10 (06) : 3339 - 3344
  • [33] Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
    Song, Yuqin
    Wu, Shang-Ju
    Shen, Zhixiang
    Zhao, Donglu
    Chan, Thomas Sau Yan
    Huang, Huiqiang
    Qiu, Lugui
    Li, Jianyong
    Tan, Tran-der
    Zhu, Jun
    Song, Yongping
    Huang, Wei-Han
    Zhao, Weili
    Liu, Herman Sung Yu
    Xu, Wei
    Chen, Naizhi
    Ma, Jun
    Chang, Cheng-Shyong
    Tse, Eric Wai Choi
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [34] Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
    Matt Shirley
    Targeted Oncology, 2022, 17 : 93 - 93
  • [35] Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
    Yuqin Song
    Shang-Ju Wu
    Zhixiang Shen
    Donglu Zhao
    Thomas Sau Yan Chan
    Huiqiang Huang
    Lugui Qiu
    Jianyong Li
    Tran-der Tan
    Jun Zhu
    Yongping Song
    Wei-Han Huang
    Weili Zhao
    Herman Sung Yu Liu
    Wei Xu
    Naizhi Chen
    Jun Ma
    Cheng-Shyong Chang
    Eric Wai Choi Tse
    Experimental Hematology & Oncology, 12
  • [36] Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton?s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases
    Guo, Yunhang
    Hu, Nan
    Liu, Ye
    Zhang, Wei
    Yu, Desheng
    Shi, Gongyin
    Zhang, Bo
    Yin, Longbo
    Wei, Min
    Yuan, Xi
    Luo, Lusong
    Wang, Fan
    Song, Xiaomin
    Xin, Lei
    Wei, Qiang
    Li, Yong
    Guo, Ying
    Chen, Shuaishuai
    Zhang, Taichang
    Zhang, Shuo
    Zhou, Xing
    Zhang, Cuining
    Su, Dan
    Liu, Junhua
    Cheng, Zhenzhen
    Zhang, Jiye
    Xing, Haimei
    Sun, Hanzi
    Li, Xin
    Zhao, Yuan
    He, Min
    Wu, Yue
    Guo, Yin
    Sun, Xuebing
    Tian, Alice
    Zhou, Changyou
    Young, Steve
    Liu, Xuesong
    Wang, Lai
    Wang, Zhiwei
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (06) : 4025 - 4044
  • [37] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [38] Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
    Allan, John N.
    Pinilla-Ibarz, Javier
    Gladstone, Douglas E.
    Patel, Krish
    Sharman, Jeff P.
    Wierda, William G.
    Choi, Michael Y.
    O'Brien, Susan M.
    Shadman, Mazyar
    Davids, Matthew S.
    Pagel, John M.
    Yimer, Habte A.
    Ward, Renee
    Acton, Gary
    Taverna, Pietro
    Combs, Daniel L.
    Fox, Judith A.
    Furman, Richard R.
    Brown, Jennifer R.
    HAEMATOLOGICA, 2022, 107 (04) : 984 - 987
  • [39] A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies
    Song, Yuqin
    Sun, Mingyuan
    Qi, Junyuan
    Xu, Wei
    Zhou, Jianfeng
    Li, Dengju
    Li, Jianyong
    Qiu, Lugui
    Du, Chenmu
    Guo, Haiyi
    Huang, Jane
    Tang, Zhiyu
    Ou, Ying
    Wu, Binghao
    Yu, Yiling
    Zhu, Jun
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 62 - 72
  • [40] Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
    Najmi, Asim
    Thangavel, Neelaveni
    Mohanan, Anugeetha Thacheril
    Qadri, Marwa
    Albratty, Mohammed
    Ashraf, Safeena Eranhiyil
    Saleh, Safaa Fathy
    Nayeem, Maryam
    Mohan, Syam
    PHARMACEUTICALS, 2023, 16 (03)
12345